pet enhanced ct scan performance in cancer

Conditions: Cancer Disease Progression

Summary: hypothesis: the investigators would like to demonstrate that diagnosis performance of pet/ct scan without and with contrast agent (combi tep), are equivalent or better than those of pet/ non enhanced ct scan (pet scan) associated with an enhanced ct scan. this research project is a pilot study given the few available data concerning this imaging exam reproducibility. this study is a prospective single center study.

hypothesis: we would like to demonstrate that diagnosis performance of pet/ct scan without and with contrast agent (combi tep), are equivalent or better than those of pet/ non enhanced ct scan (pet scan) associated with an enhanced ct scan. this research project is a pilot study given the few available data concerning this imaging exam reproducibility. this study allows us to assess the feasibility of such a large-scale study, but also to evaluate combi tep performance. from these estimates, we can then consider a comparative study to evaluate the performance of combi pet. this study is a prospective single center study.

Eligibility criteria:
inclusion criteria: any patient with a cancerous disease for which pet scan is indicated in the sor (standards - options - recommendations) fdg pet 2003 updated in 2006 must be included in the trial, in the following locations: 1. digestive cancers * colorectal cancer * preoperative evaluation in local and metastatic recurrence * location of recurrences, in case of ace increase in a previously operated patient. * esophageal cancer: initial staging. * pancreatic cancer * initial staging, * differential diagnosis with chronic pancreatitis. * liver cancer: differential diagnosis of liver metastases, cholangiocarcinoma and benign tumors in the case of an isolated hepatic localization. * digestive endocrine tumors: staging in case of normal pentetreotide scintigraphy. 2. lung cancer * initial staging, * diagnosis of lung isolated lesion \> 1 cm. 3. head and neck cancer * initial pretreatment staging, * recurrence diagnosis 4. lymphoma * initial staging of hodgkin's disease (hd), non-hodgkin's lymphoma (nhl) and aggressive follicular lymphomas, * diagnosis of minimal residual disease of hd and aggressive nhl, * early assessment of treatment response. 5. thyroid cancer: suspicion of residual disease or relapse when conventional imaging data are insufficient. 6. ovarian cancer recurrence 7. age ≥ 18 years. 8. chest-abdomen-pelvis enhanced ct scan achieved within 4 weeks before enrollment (with cuts of less than 5 mm). 9. woman of childbearing age with negative pregnancy test and / or contraception. 10. patient with informed consent signed. 11. patient affiliated to social security schemes. exclusion criteria: 1. iodine known allergy. 2. diabetes, excepted if controlled (hemoglucotest ≤ 1.6 g). 3. known renal failure (creatinine clearance \<60ml/min). 4. indications against xenetix ®: * hypersensitivity to xenetix ® or any of the excipients, * history of an immediate response or delayed cutaneous reaction to xenetix ® injection. * thyrotoxicosis. 5. pregnant or lactating women. 6. unable to undergo medical follow up for geographical, social or psychological reasons, 7. private of freedom patient and adult under a legal guardianship or unable to consent.

Keywords: pet scan ct scan diagnostic performance